QSP Multiple Myeloma Model Flyer

Division: DILIsym Services

Software capable of predicting efficacy for your novel therapeutics. Over 20 phase 2/3 clinical trials are used in training this model, spanning over 25 drug regimens and 14 distinct therapeutic agents, including steroids, protease inhibitors, immunomodulatory agents, T cell engagers, CAR-T therapies, monoclonal antibodies and combination thereof.